## Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023

LOS ANGELES, Oct. 19, 2023 /<u>PRNewswire</u>/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical stage biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that its Chief Medical Officer, Mina Pastagia, M.D., MS, will deliver a presentation at Phage Futures: Global Digital Summit 2023, which is being held virtually on October 25<sup>th</sup>.

Title: Armata Clinical Trials Overview for Acute and Chronic Infections with Systemic and Local Phage Administration

Presenter: Mina Pastagia, M.D., MS Chief Medical Officer

Time: 9:10am - 9:30am EDT (2:10pm - 2:30pm BST)

For more information or to register: https://www.kisacoresearch.com/events/phage-futures-digital

## About Phage Futures: Global Digital Summit 2023

Phage Futures: Global Digital Summit 2023 is a stage upon which to initiate all-important discussions and forge partnerships between key stakeholders worldwide. The Summit is the leading platform accelerating the translation of bacteriophages into clinically and commercially viable therapeutics and tangible commercial solutions.

## About Armata Pharmaceuticals, Inc.

Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for *Pseudomonas aeruginosa, Staphylococcus aureus*, and other pathogens. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.

## **Media Contacts:**

At Armata: Pierre Kyme Armata Pharmaceuticals, Inc. <u>ir@armatapharma.com</u> 310-665-2928 x234

Investor Relations: Joyce Allaire LifeSci Advisors, LLC jallaire@lifesciadvisors.com 212-915-2569

SOURCE Armata Pharmaceuticals, Inc.

https://investor.armatapharma.com/2023-10-19-Armata-Pharmaceuticals-Announces-Presentation-at-Phage-Futures-Global-Digital-Summit-2023